A new breakthrough study on COVID-19 by scientists from Ghent University and Lobachevsky University (Nizhniy Novgorod)

(06-09-2021) The team developed a methodology based on artificial intelligence, which allows to make prediction for clinical prognosis for COVID-19 patients.

In a recent prospective clinical study the interdisciplinary team of scientists from two different countries (Belgium and Russia) has identified a set of prediction markers which can be used to define the COVID-19 severity at the day of patient admission to the hospital.
The results of the study are recently published in the top international peer-reviewed journal “Frontiers of Immunology” which is the 5th most cited journal in Immunology. (https://www.frontiersin.org/articles/10.3389/fimmu.2021.715072/full)

About the study:

Prediction markers to define COVID-19 severity have been identified by the interdisciplinary team of Belgian and Russian scientists The recent emergence of a pathogenic SARS-coronavirus 2 (SARS-CoV-2) and its rapid spread caused a global COVID-19 pandemic with more than 4,5 million deaths worldwide during the last 1.5 years. Importantly, 14−17% of COVID-19 patients develop a severe form of the disease requiring oxygen support and admission to the intensive care unit.
Underlying medical conditions such as diabetes, chronic cardiac diseases, chronic kidney diseases, obesity, and some genetic predispositions contribute to the severity of COVID-19 but the severity of the COVID-19 in a large group of patients cannot be explained only by these factors. Importantly, it is very difficult to predict if the patient will develop a severe form of disease, and a more complex multifactorial analysis and prediction methods are needed to make a prognosis for the development of severe disease upon hospitalization to initiate early treatment and possibly achieve better outcomes. Therefore, a prediction of the severity of COVID-19 and prognosis of the disease development from the first days is outmost important for providing adequate and timely management to reduce patients’ mortality.

In this study, the team developed a methodology based on artificial intelligence, which allows to make prediction for clinical prognosis for COVID-19 patients. Prof. Dr Krysko (Ghent University): “This methodology allows to make prediction with an accuracy of about 87% whether the patient will develop a severe disease. These results pave the way for the development of new prognostic criteria and markers for COVID-19 patients and will help in the management of COVID-19 patients’’. First author dr. Olga Krysko (Ghent University): “The advantage of these identified markers is that these markers can be easily measured in most conventional clinical laboratories worldwide, making this prediction analysis accessible for many hospitals.

About the research team:

From left to right: Prof. Dr. Maria Vedunova (Lobachevsky University), Dr. Olga Krysko and Prof. Dr. Dmitri Krysko (UGent).

From left to right: Prof. Dr. Maria Vedunova (Lobachevsky University), Dr. Olga Krysko and Prof. Dr. Dmitri Krysko (UGent).

The study was realized by an interdisciplinary team of Russian and Belgian scientists consisting of immunologists, mathematicians, and clinicians under supervision of Prof. Dr. Dmitri Krysko (Cell Death Investigation and Therapy Lab, Department of Human Structure and Repair, Ghent University, Belgium) and Prof. Dr. Maria Vedunova (National Research Lobachevsky State University of Nizhniy Novgorod, Russia). This research is a part of an ongoing collaboration between prof. Dr. Dmitri Krysko and Prof. Dr. Maria Vedunova, strengthened by a signed scientific cooperation agreement between the two universities.

Consult the full version of the article through this link
https://www.frontiersin.org/articles/10.3389/fimmu.2021.715072/full